Overactive Bladder, Urgency-frequency Syndrome, Urinary Frequency More Than Once at Night
Conditions
Brief summary
Overactive bladder (OAB) is a chronic disorder with an overall prevalence in the adult population of over 10%, but that may exceed 40% in elderly groups. Most overactive bladder treatments are aimed at decreasing urgency incontinence episodes. The purpose of this study is to determine whether an at-home transvaginal electrical stimulation (TES) program works to alleviate symptoms of urgency in patients with urinary urgency and frequency without incontinence. This is a cross-over trial. Women \>18 yo presenting with OAB-dry will be randomized to receive one of two TES at home programs for 4 weeks. After completion of the program, the participant's symptoms will be assessed with standardized patient questionnaires. There will then be a 3 week washout period followed by the second at-home TES program. At the completion of the second program, the participant's symptoms will be assessed with the same standardized questionnaires. The participants will be followed for 6 months following the completion of the TES program.
Detailed description
This will be a prospective randomized cross over trial. We will recruit women who present to clinic to see a Female Pelvic Medicine and Reconstructive Surgery, fellowship-trained provider within the UCLA Health System with the symptoms of OAB-dry and have failed or decline anti-cholinergic therapy. Screening: Patients will be made aware of the study by their physician. Interested subjects will interact with study staff in person or by telephone for a complete description of the study. If they wish to continue, they will be screened for eligibility by study staff. If eligible, they will be given as much time as they wish to complete the process of informed consent and have their questions answered. Consent will be obtained electronically using the RedCap system. After informed consent, subjects will be asked to complete intake questionnaires, sent through the RedCap site. These questionnaires include the International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), female GenitoUrinary Pain Index (fGUPI), Pelvic Organ Prolapse Distress Inventory (POPDI-6) portion of the Pelvic Floor Disability Index (PFDI), the first 8 questions of the OverActive Bladder questionnaire (OAB-q), the last question of the AUA symptom score, and the Urgency Perception Scale: UPC. After informed consent, study staff will access subjects' medical records to obtain the results of standard care procedures that are regularly performed for patients with this symptomatology, specifically, pelvic exam and urodynamics. Participants will be asked to make a research visit for training and to obtain materials. They will be issued the iStim device. Both groups will be oriented to the vaginal stimulation device which includes the iStim TENS unit and Transvaginal Probe. The iStim TENS unit delivers a bipolar square wave that can be delivered over a range of 0 to 100 mA. On the TENS unit the patient can set frequency, duration of stimulation, pulse duration, and amplitude. During each participant's in-person visit they will be instructed by trained study staff on how to use the electrical stimulation. Patients will be randomized to treatment A followed by treatment B (Group 1) or treatment B followed by treatment A (Group 2). The patients will be blinded to which treatment they are receiving first. Each treatment phase will be 4 weeks in duration. The washout period between phases will be three weeks. Patients will be given a log to record each session completed at home in order to determine compliance. They will also be asked to record the amplitude achieved for each session in the treatment phase. Patients will be able to report adverse events electronically through RedCap or by contacting study staff directly. At the end of each 4-week treatment patients will be asked to complete the same intake questionnaires again with the addition of the select questions from the modified version of the Overactive Bladder Patient Satisfaction with Treatment Questionnaire (OAB-PSTQ) and Patient Global Assessment (PGA) which assesses their perception of the intervention. At the end of the intervention, participants will be asked to complete a bladder diary again using the same IUGA bladder diary. Participants will be followed through their medical record for 6 months after completion of study activities. Further OAB therapies tried will be recorded as well as pelvic exams and/or urodynamics done as part of their standard care. They will be asked to complete the set of intake questionnaires once more at the end of 6 months.
Interventions
DEVICEiStim TENS unit and Transvaginal Probe
iStim TENS unit and Transvaginal Probe are both commercially available products. TENS units work by delivering small electrical impulses through electrodes either attached to the skin or through a transvaginal probe. iStim transvaginal probe will be inserted vaginally to provide transvaginal electrical stimulation.
Sponsors
University of California, Los Angeles
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Masking description
Participants will be masked to which treatment they are receiving in which order. They will be randomly assigned to one of two groups. The randomization assignments will be generated by the principal statistician in the UCLA Department of Urology with a random number generator algorithm in Microsoft Excel so that the proposed recruited patients will be randomly assigned to control or intervention group in an equal amount per group. This will be stored in a central location on a password protected system on the UCLA Health Box for the research staff to access and as each patient is randomized they will use the next available group assignment on the sheet and cross them off. This will be closely monitored to maintain appropriate use. The randomization will occur at the time of enrollment.
Intervention model description
Patient will then be randomized to treatment A followed by treamtent B (Group 1) or treatment B followed by treatment A (Group 2).
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 120 Years
Healthy volunteers
Yes
Inclusion criteria
* Female * Age \> 18 years old * English speaking * OAB symptoms for greater than 3 months duration defined as: * Urgency: Answer to OAB-q3 \> 4\] * Frequency: greater than 8 voids on bladder diary during waking hours and OAB-q1 \> 3 * No urinary urge incontinence: OAB-q8 \< 2 and OAB-q4 \< 2 * No significant pelvic pain: fGUPI4 \< 4
Exclusion criteria
* Age less than 18 * Pregnancy * Vaginal infection or lesion * Neurogenic bladder * Immunocompromised state (hx of transplant, on immunosuppressing drugs) * PVR \>150cc * Urinary tract infections * Neurogenic bladder * Reduced perception of vaginal sensation * Metallic implants * Implanted electrical devices (i.e. pace maker)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Urinary urgency | This will be the difference in score from the date of enrollment to the end of both treatment arms. This will range from 11 weeks to 20 weeks. | The primary outcome is the change in participant's reported urgency as measured by the composite score of the first 8 questions of the OAB-q questionnaire. The questionnaire is out of 8 with higher scores corresponding with more bother from urinary urgency. The primary outcome is the difference between the pre-treament and post-treatment scores. The range is 0 to 48 with a larger difference corresponding to more improvement in patient's urgency over the study period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of assigned treatment sessions that were successfully completed | 4 weeks | Number of home programs completed compared to planned treatments based on paper treatment log completed by patient. Range is 0 to 100% completion. |
| Change in Urinary Urgency Episodes | This will be the difference in score from the date of enrollment to the end of both treatment arms. This will range from 11 weeks to 20 weeks. | Change in number of urgency episodes (per 24 hours) as measured on the voiding diaries. This will be the difference in number of urgency episodes pretreatment compared to posttreatment. The range is 0 to 10 urgency episodes. |
| Change in number of micturitions per 24 hours | This will be the difference in score from the date of enrollment to the end of both treatment arms. This will range from 11 weeks to 20 weeks. | Change in number of micturition episodes (per 24 hours) as measured on the voiding diaries. This will be the difference in number of micturition episodes pretreatment compared to post-treatment. The range is 0 to 20 micturition episodes. |
Countries
United States
Outcome results
None listed